Journals / Nöropsikiyatri Arşivi / 2011 / Cilt: 48 - Sayı: 2

Dikkat eksikliği hiperaktivite bozukluğunda tamamlayıcı ve alternatif tedaviler

Complementary and alternative treatments of attention deficit hyperactivity disorder

Pages
94–102
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here, the most common complementary and alternative treatments of ADHD will be reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric conditions estimated to affect 5-10% of the children.
📊
Key Findings & Data:It is a chronic condition and frequently persists into adulthood.
💡
Conclusion & Impact:Here, the most common complementary and alternative treatments of ADHD will be reviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric conditions estimated to affect 5-10% of the children. It is a chronic condition and frequently persists into adulthood. Approved pharmacological agents for the treatment of ADHD include psychostimulants and atomoxetine. However,non-pharmacological treatment seeking and the use of complementary and alternative medicine are on the rise. Here, the most common complementary and alternative treatments of ADHD will be reviewed.

Özet

Dikkat eksikliği hiperaktivite bozukluğu (DEHB) çocukların yaklaşık %5-10 kadarını etkileyen en yaygın psikiyatrik durumlardan biridir. Kronik seyirli bir bozukluktur ve sıklıkla erişkinliğe kadar sürer. DEHB tedavisinde kullanımı onaylanmış farmakolojik ajanlar psikostimülanları ve atomoksetini içerir. Ancak ilaç dışı tedavi arayışları ve tamamlayıcı ve alternatif tıp kullanımı artış göstermektedir.Burada, DEHB'de en sık kullanılan tamamlayıcı ve alternatif tedaviler gözden geçirilecektir.

🔖

Cite This Article

KILINÇASLAN, A., TUTKUNKARDAŞ, M. D., MUKADDES, N. M. (2011). Dikkat eksikliği hiperaktivite bozukluğunda tamamlayıcı ve alternatif tedaviler. Nöropsikiyatri Arşivi, Cilt: 48 - Sayı: 2, 94–102. https://ajindex.com/articles/292647

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Text Revision. 4th ed. Washington DC: American Psychiatric Association
  2. Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007
  3. Greenhill L, Beyer D, Finkleson J et al. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder. J Atten Disord 2002
  4. 6(Suppl 1):89-100. 4. McCracken J, Biederman J, Greenhill L et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 2003
  5. Wigal S, McGough J, McCracken J et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005
  6. Wolraich M, Greenhill L, Pelham W et al. Randomized, controlled trial of oros methylphenidate once a day in children with attentiondeficit/ hyperactivity disorder. Pediatrics 2001
  7. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001
  8. E83. 8. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003
  9. Kutcher S, Aman M, Brooks S et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004
  10. No authors listed. Guanfacine extended-release (intuniv) for ADHD. Med Lett Drugs Ther 2010
  11. Biederman J, Melmed RD, Patel A et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008
  12. e73-e84. 12. Sallee FR, Lyne A, Wigal T et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attentiondeficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2009
  13. Pelham WJ, Whe